Biotech News

Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics (ARQT)Arcutis BiotherapeuticsEarnings

Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth Raised 2026 full-year net product sales guidance to $535 million–$545 million Partnered with World Champion

Related news

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

Stock data

Close
27.17 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States